Review article · 2020 · Open access
Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product
Stem Cells Translational Medicine, 10(2), 198–208 · Published 18 September 2020 · DOI 10.1002/sctm.20-0242
In brief
“Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product” is a 2020 review article by Balendu Shekhar Jha and 2 co-authors, published in Stem Cells Translational Medicine. OpenAlex counts 76 citations as of 21 November 2026, which puts it in the top 2% of works published in 2020 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Stem Cells Translational Medicine.
- Citations
- 76
- Most cited in
- 2024 (20)
- Field-weighted impact
- 0.62
- References
- 74
- Authors
- 3
Abstract
Induced pluripotent stem cells (iPSC)-based therapies have been hailed as the future of regenerative medicine because of their potential to provide treatment options for most degenerative diseases. A key promise of iPSC-based therapies is the possibility of an autologous transplant that may engraft better in the longer-term due to its compatibility with the patient's immune system. Despite over a decade of research, clinical translation of autologous iPSC-based therapies has been slow-partly due to a lacking pre-defined regulatory path. Here, we outline regulatory considerations for developing an autologous iPSC-based product and challenges associated with the clinical manufacturing of autologous iPSCs and their derivatives. These challenges include donor tissue source, reprogramming methods, heterogeneity of differentiated cells, controls for the manufacturing process, and preclinical considerations. A robust manufacturing process with appropriate quality controls and well-informed, prospectively designed preclinical studies provide a path toward successful approval of autologous iPSC-based therapies.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Jha, B. S., Farnoodian, M., & Bharti, K. (2020). Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product. Stem Cells Translational Medicine, 10(2), 198–208. https://doi.org/10.1002/sctm.20-0242
MLA 9
Jha, Balendu Shekhar, et al. “Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product.” Stem Cells Translational Medicine, vol. 10, no. 2, 2020, pp. 198–208. https://doi.org/10.1002/sctm.20-0242.
Chicago
Jha, Balendu Shekhar, Mitra Farnoodian, and Kapil Bharti. 2020. “Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product.” Stem Cells Translational Medicine 10 (2): 198–208. https://doi.org/10.1002/sctm.20-0242.
Harvard
Jha, B. S., Farnoodian, M. and Bharti, K. (2020) ‘Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product’, Stem Cells Translational Medicine, 10(2), pp. 198–208. doi:10.1002/sctm.20-0242.
IEEE
B. S. Jha, M. Farnoodian, and K. Bharti, “Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product,” Stem Cells Translational Medicine, vol. 10, no. 2, pp. 198–208, 2020, doi: 10.1002/sctm.20-0242.
BibTeX
@article{jha2020regulatory,
title = {{Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product}},
author = {Jha, Balendu Shekhar and Farnoodian, Mitra and Bharti, Kapil},
journal = {Stem Cells Translational Medicine},
year = {2020},
volume = {10},
number = {2},
pages = {198--208},
doi = {10.1002/sctm.20-0242},
url = {https://doi.org/10.1002/sctm.20-0242}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2021 | 10 | |
| 2022 | 8 | |
| 2023 | 10 | |
| 2024 | 20 | |
| 2025 | 10 | |
| 2026 | 18 |
Its field-weighted citation impact is 0.62: it has been cited 0.62 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- induced pluripotent stem cells
- autologous cell therapy
- regulatory considerations
- Investigational New Drug application
- clinical translation
- cell manufacturing
- cellular heterogeneity
- quality control
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Jha, B. S., Farnoodian, M., & Bharti, K. (2020). Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product. Stem Cells Translational Medicine, 10(2), 198–208. https://doi.org/10.1002/sctm.20-0242
How many times has this paper been cited?
76 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Stem Cells Translational Medicine: sign in and open the PDF from this page.
Who wrote this paper?
Balendu Shekhar Jha, Mitra Farnoodian, Kapil Bharti.
What is the DOI of this paper?
10.1002/sctm.20-0242, permanently at https://doi.org/10.1002/sctm.20-0242. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.